October 22, 2019 by BioHouston BreviTest Awarded SBIR Phase II Grant from National Institute on Drug Abuse To Commercialize Device for Rapid Opioid Testing
October 16, 2019 by BioHouston Hope Biosciences Opens First Phase I/II Stem Cell Trial for Brain Injury Treatment
October 14, 2019 by BioHouston Forbius Completes Enrollment into Phase 1a Solid Tumor Trial of AVID200, First-in-Class TGF-beta 1 & 3 Inhibitor; Closes Series C Financing
October 10, 2019 by BioHouston Forbius: Phase 2 Clinical Data with Tumor-Selective Anti-EGFR ADC AVID100 Featured at AACR-NCI-EORTC and World ADC San Diego
October 8, 2019 by BioHouston Salarius Pharmaceuticals Adds Memorial Sloan Kettering Cancer Center and Nationwide Children’s Hospital as Clinical Sites for Phase 1/2 Trial of Seclidemstat in Ewing Sarcoma
September 25, 2019 by BioHouston Tom Luby, director of the TMC Innovation Institute, reflects on six months at the helm